Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A low-cost genome sequencing technique that was used by thousands of laboratories globally to spot COVID-19 variants will be extended to cover all pathogens, in an ambitious new Wellcome Trust-funded project launched today. The ARTIC-2 project is led by the University of Birmingham and brings together researchers from the Democratic Republic of Congo, Ghana and Kenya with expertise in responding to numerous viral threats using genomic surveillance, including recent outbreaks of Ebola virus and Mpox in Africa.

African researcher in lab

The ARTIC-2 project will develop the underlying technology for the surveillance of emerging pathogens around the world. ARTIC-2 will work alongside the Africa CDC, Asia Pathogen Genomics Initiative and the WHO International Pathogen Surveillance Network to ensure that processes can then be rolled out worldwide.

Genomic surveillance is a powerful tool in the fight against infectious diseases. By analysing the genetic makeup of pathogens like viruses or bacteria, scientists can track the spread of outbreaks and understand their evolution over time. This information can help public health officials predict future outbreaks, develop targeted treatments, and implement effective control measures. It also aids in tracing the source of an outbreak and understanding how it has been transmitted between different populations. Easy access to genomic sequencing will enable public health laboratories around the world to respond more quickly and effectively to outbreaks of new and emerging viruses as well as better understand the mutations that occur randomly which lead to immune evasion or increased resistance to treatments.

A key element of the ARTIC-2 programme will be the continued development of a low-cost laboratory protocols and equipment that significantly reduce the cost of sequencing. The team are focused on reducing the cost of sequencing to under £10 per sample, reducing costs by focusing on open-source methods and reducing the reliance on expensive proprietary equipment and reagents. Lower costs allow more labs to perform sequencing where it is badly needed such as in low- and middle-income countries (LMIC) and the global south.

The project will also improve the way in which data is shared between researchers through a new initiative called Pathoplexus. Better data sharing can significantly improve outbreak response and public health decision-making as it allows for more accurate monitoring and tracking of disease transmission, enabling early detection and control efforts. The team also aims to rationalise the approach to develop a knowledge engine that will link all aspects of existing processes and tools with new learning to provide a universal and global toolkit for surveillance of pathogenic threats.

Professor Elijah Songok, the acting Director General at the Kenya Medical Research Institute (KEMRI), said: 'KEMRI is at the forefront of the development and adoption of cutting-edge technologies to improve health. We saw the impact genomic surveillance during the COVID 19 pandemic, and this research provides a much-needed tool in ensuring we are adequately equipped in identification of emerging pathogens and the continued efforts in the fight against infectious diseases.'

Professor Nick Loman, Professor of Microbial Genomics and Bioinformatics at the University of Birmingham and lead researcher for ARTIC-2, said: 'ARTIC-2 will help to realise the ambition that any laboratory, anywhere in the world could access affordable, high-quality genomic sequencing for their work. During the global pandemic, sequencing was one of the most important tools at our disposal to understand how the coronavirus was changing to help inform development of new treatments and vaccines as well as public health policies. With funding from Wellcome to develop ARTIC-2 we can develop a universal, global toolkit and learning platform that means any endemic virus or pathogen around the world can be sequenced quickly and cheaply.'

Dr George Githinji, Head of Bioinformatics at the KEMRI-Wellcome Trust Research Programme, said: 'The impact of genomic surveillance has yet to be fully realised in LMIC settings. The Programme has shown how we can potentially use sequencing as a tool to fight disease outbreaks and provide timely interventions. Our work with the Public health Laboratories in Kenya has shown how useful it is to ensure capacity building of public health teams to ensure that this technology translates to real life solutions for health improvement”.

Dr Placide Mbala Kingebeni, National Institute of Biomedical Research in the Democratic Republic of Congo and co-researcher on the project said: 'The ARTIC-2 initiative represents a major leap forward in our ability to detect and respond to infectious disease threats in real time. By expanding genomic surveillance beyond high- consequence viruses to include endemic and emerging pathogens, we are strengthening our capacity to act swiftly and effectively in the face of new outbreaks. This funding will enable us to build a more robust and adaptable response system; one that is accessible, cost- effective, and capable of guiding public health action where and when it is needed most.'

Similar stories

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

New study improves early detection of life threatening infection in children across South and South East Asia

A new study published in Nature Medicine suggests that simple, low-cost tools could help health workers identify children at risk of life-threatening infection earlier, improving access to urgent care in across South and South East Asia.